S Tag Peptide (A6007): Practical Fusion-Tag Workflow

S Tag Peptide is a 15-amino-acid oligopeptide derived from the N-terminus of pancreatic ribonuclease A. At the DNA level, the corresponding S-peptide fusion tag can be placed at either the N- or C-terminus of a recombinant target protein. The charged and polar sequence is highly soluble and may support protein solubility improvement when used as a fusion, while the encoded tag also provides an epitope for recombinant protein detection and antibody-assisted purification.

No directly matched paper evidence was supplied for SKU A6007. The practical guidance below therefore separates product-dossier specifications from workflow recommendations and avoids assigning a universal improvement in expression, yield, or binding performance. For identity and handling details, consult the S Tag Peptide product page from APExBIO.

What This Product Solves

Many recombinant proteins are difficult to detect or recover because expression is low, the protein partitions into an insoluble fraction, or the purification method lacks a convenient epitope. An S Tag Peptide fusion addresses these workflow problems through a small, antibody-compatible sequence rather than a large independently folded domain. This makes it suitable for experiments in which tag size, aqueous handling, and immunodetection are important.

The peptide corresponds to the S15 fragment of RNase A. The free S15 fragment is inactive alone, although the complementary RNase fragment can restore ribonuclease activity when the fragments are complexed. That biochemical origin should not be confused with using free S Tag Peptide as an RNase catalyst. In routine molecular biology, its main utility is as a fusion epitope and protein solubility enhancer peptide.

When to use the tag

• Use an encoded S-peptide fusion tag when the primary readout is anti-S-Tag antibody detection by immunoblot, immunoassay, or a related antibody-based format.
• Consider it for protein expression and purification studies in which a small, highly soluble terminal sequence may help maintain the target in an aqueous fraction.
• Use the free synthetic peptide mainly as a reference, assay-control, or reagent for method development; it is not equivalent to a genetically fused tag.

The article S Tag Peptide: The Versatile Protein Solubility Enhancer Tag provides broader context on solubility and detection, whereas this guide focuses on construct design, handling, and QC. The related S Tag Peptide: Practical Fusion Tag Workflow complements this article by discussing terminal fusion logic and the limits of free-peptide use.

Protocol Parameters

• Assay/parameter: Fusion orientation. Value: N- or C-terminal genetic fusion. Applicability: Recombinant construct design. Rationale: Either terminus can provide an antibody-accessible tag, but the target protein should be tested in the orientation that best preserves its expression and function. Evidence basis: Product dossier.
• Assay/parameter: Peptide length. Value: 15 amino acids. Applicability: Sequence confirmation and construct verification. Rationale: Confirm the complete tag sequence and reading frame before interpreting detection or solubility results. Evidence basis: Product specification.
• Assay/parameter: Molecular weight. Value: 1748.91 Da for the supplied peptide. Applicability: Free-peptide preparation and analytical identity checks. Rationale: Use the listed mass when calculating the amount of solid needed for a defined molar preparation. Evidence basis: Product specification.
• Assay/parameter: Solvent compatibility. Value: Solubility is at least 50 mg/mL in water and at least 174.9 mg/mL in DMSO; the peptide is insoluble in ethanol. Applicability: Free-peptide reconstitution and assay setup. Rationale: Select water or DMSO and exclude ethanol from the planned stock-preparation workflow. Evidence basis: Product specification.
• Assay/parameter: Storage. Value: Desiccated at -20 °C as a solid; solutions are for short-term use only. Applicability: Inventory and stock management. Rationale: Minimize moisture exposure and avoid treating a solution as a long-term storage format. Evidence basis: Product specification.
• Assay/parameter: Working concentration. Value: Pilot-dependent; no universal concentration is specified. Applicability: Detection, binding, or control experiments. Rationale: Titrate within the validated assay range rather than transferring a concentration from an unrelated antibody or peptide system. Evidence basis: Workflow recommendation, not a product specification.

Workflow Setup and QC Checklist

1. Design and verify the construct

1. Define whether the S-peptide fusion tag will be placed at the N- or C-terminus. Record the exact amino-acid sequence, reading frame, start and stop elements, and any linker used.
2. Check the target sequence for an intact tag and confirm that the chosen orientation does not remove a required signal peptide, transit sequence, or catalytic terminus.
3. Sequence-verify the final plasmid. Do not infer correct tagging from antibiotic selection or colony growth alone.

2. Establish expression and solubility controls

Run the tagged construct beside an untagged or alternative-tag control when protein solubility improvement is an experimental endpoint. After expression, analyze total lysate, clarified soluble material, and insoluble material separately. This distinguishes increased recovery in the soluble fraction from an increase in total expression. Keep host strain, induction design, harvest timing, and lysis conditions consistent across the comparison.

3. Set up detection or purification

For recombinant protein detection, use a commercially available anti-S-Tag antibody with an appropriate positive and negative control. Include a no-tag lysate to assess nonspecific binding and a tagged sample known to contain the target when establishing the assay. For purification, use an antibody-based capture format only after confirming that the selected matrix is compatible with the S-tag sequence and the sample buffer. Elute and analyze fractions independently rather than judging recovery from a single pooled sample.

4. Handle the free peptide correctly

Allow the solid to equilibrate in a dry environment before opening, then prepare a small working solution in water or DMSO according to the assay requirement. Inspect the solution for visible precipitation before use, label solvent and preparation date, and reserve solutions for short-term experiments. Do not use ethanol to dissolve or dilute this product. Maintain a preparation record containing mass, solvent, calculated concentration, operator, and storage condition.

5. Confirm identity and performance

• Use sequence records for construct identity and an analytical method appropriate to the laboratory for peptide or fusion-protein confirmation.
• For antibody workflows, document signal in the tagged positive control, background in the no-tag control, and the result in the target sample.
• For solubility studies, report soluble and insoluble fractions separately and avoid describing a target as improved unless the same recovery calculation and controls were used.

Common Failure Modes and Fixes

No anti-S-Tag antibody signal

Check the tag sequence, reading frame, terminal orientation, and sample transfer before changing the antibody concentration. A folded or partially degraded target can also reduce epitope accessibility. Test a known tagged control and a no-tag negative control to separate reagent failure from construct failure.

Target remains insoluble

The S Tag Peptide may support solubility but does not guarantee soluble expression for every protein. Compare N- and C-terminal placement, confirm that the insoluble band contains the intended target, and review expression and lysis conditions. Do not attribute the result to the tag until total expression and fraction distribution have been measured.

Purification gives weak recovery

Verify that the capture reagent recognizes the S-tag sequence and that the tag remains attached after expression and processing. Examine flow-through, wash, and elution fractions separately. If the target is soluble but absent from the elution, investigate antibody-matrix compatibility before redesigning the entire construct.

Free-peptide stock precipitates

Confirm that ethanol was not used and that the selected solvent is water or DMSO. Prepare a smaller stock, mix until uniform, and avoid extended storage in solution. If precipitation persists, record the solvent and concentration and validate a new preparation rather than assuming the material is inactive.

The peptide is treated as an RNase reagent

The isolated S15-derived peptide does not retain RNase activity by itself. Use it as a tag-related reagent or control, not as an independent substitute for intact RNase A or a reconstituted complementary-fragment system.

Scope and Limitations

This product is best considered a small fusion epitope with high aqueous solubility, not a self-folding solubility domain. The dossier supports N- or C-terminal genetic fusion, antibody-based detection and purification, the listed solvent behavior, and the stated storage condition. It does not establish a universal increase in soluble yield, a fixed antibody affinity, or compatibility with every expression host, buffer, linker, or purification matrix.

Free synthetic peptide and genetically encoded S-tagged protein should be evaluated separately. The free peptide has its own molecular weight and solvent requirements, whereas the fusion protein has a context-dependent apparent mass, folding behavior, and antibody accessibility. In the absence of directly matched paper evidence, use pilot comparisons and explicit controls before extending the tag to a new target or assay format.

Conclusion

S Tag Peptide A6007 provides a practical route to S-peptide fusion tag designs requiring recombinant protein detection, antibody-assisted purification, and a small charged sequence for protein solubility improvement. The most reliable workflow combines sequence verification, terminal-orientation testing, soluble-versus-insoluble fraction analysis, antibody controls, and disciplined free-peptide storage. Keep the product’s RNase-fragment origin and solvent limitations distinct from the behavior of the engineered fusion protein.